Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib
AstraZeneca AB
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
1 trial -
Capivasertib, Placebo for capivasertib film-coated tablet for oral use, ABIRATERONE ACETATE, Capivasertib
AstraZeneca AB
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency
1 trial -
Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788
Institut für biomedizinische Analytik NMR-Imaging GmbH
Prostate Cancer
1 trial -
Placebo for Capivasertib, PACLITAXEL, Capivasertib, Capivasertib
AstraZeneca AB
Triple-negative Breast Cancer
1 trial -
Placebo to capivasertib, Capivasertib, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Capivasertib, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung
AstraZeneca AB
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1 trial -
Oleclumab, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, PACLITAXEL, Capivasertib, DS-8201a
AstraZeneca AB
First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
1 trial -
TEMOZOLOMIDE VIATRIS 5 mg, gélule, Capivasertib, TEMOZOLOMIDE VIATRIS 100 mg, gélule, VINORELBINE ACCORD 20 mg, capsule molle, Votubia 3 mg dispersible tablets, Bavencio 20 mg/mL concentrate for solution for infusion, Peposertib, INC280, Enasidenib Mesilate, Futibatinib, TEMOZOLOMIDE VIATRIS 20 mg, gélule, Capivasertib, VINORELBINE ACCORD 30 mg, capsule molle, INC280, Enasidenib Mesilate, Votubia 5 mg dispersible tablets, Votubia 2 mg dispersible tablets, Capivasertib
Institut für biomedizinische Analytik NMR-Imaging GmbH
pediatric cancer
1 trial -
A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants
AstraZeneca AB
Healthy participants
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources